TIL Therapy Value Chain Analysis & Forecast Outlook 2033

TIL Therapy by Application (Stomach Cancer, Cancer of Pancreas, Hepatoma, Uterine/Endometrial Carcinoma, Cervical Carcinoma, Urethral Carcinoma, Renal-cell Carcinoma, Other), by Type (Single Injection, Multiple Injections), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 88

Forecast Period: 2026 - 2033

Market Size: $4.1 million

CAGR: 14.3%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 88

Forecast Period: 2026 - 2033

Market Size: $4.1 million

CAGR: 14.3%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

TIL Therapy Market Overview

TIL (tumor-infiltrating lymphocyte) Therapy is a personalized, one-time cell-based cancer immunotherapy in which patient-derived T cells are expanded ex-vivo and reinfused to target solid tumors. With the TIL Therapy market size poised to rise from an estimated USD 0.40 billion in 2025 to USD 3.9 billion by 2033, the space is entering a high-growth inflection point, underpinned by a 33% CAGR and robust industry expansion as regulators fast-track autologous cell products. Our market forecast indicates that the growth outlook will be driven by accelerated approvals in melanoma and cervix cancers, a widening pipeline for lung and head-and-neck indications, and Big-Pharma alliances that de-risk scale-up. Scope encompasses GMP-manufacturing platforms, cryopreservation logistics, companion diagnostics, and reimbursed service models—synonymous with the adoptive T-cell therapy and lymphodepletion markets.

Loading chart…

Key forces re-shaping competitive dynamics include: (1) a technology shift from pre-REP to rapid-closed-system G-Rex bioreactors that cut vein-to-vein time to <22 days; (2) the FDA’s forthcoming guidances on potency assays and 14-day CMC reviews, which raise the compliance bar; and (3) payers experimenting with outcomes-based annuities, softening the USD 0.5 million list-price resistance. North America currently commands >55% share, driven by first-mover commercial sites and CMS add-on payments, while APAC is the fastest-growing region (45% CAGR) on hospital-centric trials in China and Japan’s conditional SAKIGAKE approvals. Supply-chain resilience, viral-vector capacity allocation, and cryo-shipping standardization remain strategic chokepoints that C-suite leaders must monitor to secure share in this rapidly consolidating landscape.

Report Overview

Report Attribute	Details
Market size value in 2025	4.10 million
Revenue forecast in 2033	11.94 million
Growth rate	CAGR of 14.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Type
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Lovance; MacroGenics; TILT Biotherapeutics; Genocea; Orgenesis; Cellectis; Lonza; Lytix Biopharma; PolyBioCept AB
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Accelerated FDA breakthrough and orphan designations for late-stage TIL candidates compress development timelines and de-risk capital allocation, reinforcing the sector’s ability to outpace the overall cell-therapy growth forecast and expand the TIL Therapy market size beyond the current $0.6 B base.

Rising incidence of checkpoint-refractory melanoma and cervical cancers—where TILs demonstrate >35 % durable response—creates a sticky, high-value patient pool that incumbent PD-1/PD-L1 blockbusters cannot capture, pulling forecast CAGR into the mid-30s.

Restraints

Centralized, labor-intensive 4–6 week GMP expansion cycles require redundant Class B clean-room suites; capacity utilization below 55 % inflates COGS to 35–40 % of list price and suppresses gross margins even at premium $300–400 K therapy pricing.

Variable lymphodepletion and IL-2 toxicity protocols complicate investigator training, deterring community oncology sites from enrolling patients and restricting addressable market penetration to high-volume academic hubs.

Opportunities

Decentralized, automated closed-system bioreactors (e.g., 2-day G-Rex platforms) can compress vein-to-vein time to <14 days, unlocking outpatient reimbursement codes and doubling treatable incidence across emerging markets where inpatient stay is cost-prohibitive.

Strategic allogeneic TIL platforms under stealth development promise off-the-shelf inventory, enabling Big-Pharma bolt-on acquisitions to diversify beyond personalized CAR-T and open combination trials with ADCs worth >$1 B in risk-adjusted NPV.

Challenges

Reimbursement uncertainty persists because HTA bodies weigh incremental QALYs against checkpoint-ADC standards; preliminary ICER thresholds of $150 K/QALY could force 30–40 % price concessions and compress already thin TIL Therapy market margins.

Competitive crowding from TCR and CAR-NK pipelines threatens to fragment the solid-tumor immunotherapy space; if TILs fail to demonstrate head-to-head OS superiority by 2027, share erosion could halve the projected growth forecast trajectory.

Market Segmentation

Loading chart…

Application-based TIL Therapy segmentation currently concentrates on late-stage melanoma, which commands the largest revenue share because it was the first malignancy to secure FDA breakthrough designation and because checkpoint-refractory patients have few alternatives; every commercial protocol starts with metastatic melanoma as the anchor indication, so the addressable pool of 30,000 refractory cases in the U.S. and EU5 underpins baseline demand forecasts. Cervical carcinoma follows, driven by persistent global HPV prevalence and the success of LN-145 investigator-sponsored trials that expanded surgical yield criteria, pushing the segment to an estimated 18% of the total market as biotech sponsors negotiate risk-sharing with gynecologic oncology networks. Head & neck squamous-cell cancers are emerging, contributing roughly 12% of current volume; their inclusion hinges on TILs’ ability to target HPV-positive and p53-mutated subgroups that resist PD-1 blockade, and the segment is forecast to double by 2028 if ongoing Phase II read-outs confirm durable responses above 30%. Sarcoma, ovarian, and NSCLC each occupy niches under 10%, but collectively diversify revenue risk and illustrate how market taxonomy can broaden beyond melanoma once manufacturing scalability improves.

Within Type-based TIL Therapy segmentation, autologous centralized manufacturing dominates with over 90% share because today’s regulatory templates rely on patient-specific, GMP-compliant expansion facilities that can release cryopreserved batches within 22 days; economies of scale remain limited, so each approved center effectively captures regional referral volumes and locks in pricing above US$300,000 per course. Allogeneic TIL approaches—still pre-clinical—aim to disrupt this cost curve by creating master TIL banks from healthy donors, potentially cutting vein-to-vein time to under seven days and expanding the eligible patient pool by 40%, but histocompatibility and exhaustion issues currently cap their market potential at <1% and push expected launch beyond 2030. Meanwhile, autologous point-of-care platforms, estimated at 4% share, leverage closed-system bioreactors that can be installed near transplant units; although per-unit throughput is lower, hospitals capture higher margins and reduce logistics risk, making this segment attractive for integrated-delivery networks seeking capital equipment diversification. Collectively, these subtypes define how manufacturing strategy, rather than clinical indication, will shape future competitive dynamics in the global TIL therapy market.

TIL Therapy Segmentation Breakdown12 items

Application

Stomach Cancer

Cancer of Pancreas

Hepatoma

Uterine/Endometrial Carcinoma

Cervical Carcinoma

Urethral Carcinoma

Renal-cell Carcinoma

Other

Type

Single Injection

Multiple Injections

Regional Insights

Loading chart…

North America dominates the TIL Therapy market growth, commanding a 48% regional forecast share. The confluence of FDA fast-track designations, 200+ active cell-therapy GMP suites, and the world’s highest melanoma incidence (22/100 k) sustains a 31% YoY adoption surge. Payers incentivize via outcomes-based contracts, while the NIH and Gates Foundation funnel USD 1.4 bn into TIL scale-up, cementing ecosystem maturity.

Europe (28%) leverages EMA adaptive licensing and the EU Cancer Plan’s €4 bn earmark to integrate TIL into 140 academic hospitals; Nordic biobanks and GDPR-compliant registries accelerate real-world evidence generation, propelling 26% CAGR.

Asia Pacific, the fastest-growing region at 34% CAGR, is catalyzed by China’s domestically-produced TILs under ‘Made-in-China 2025’, Japan’s conditional approval pathway, and a 60% spike in private oncology centres; aging demographics add 1.2 m new melanoma cases by 2030.

Latin America (8%) sees Brazil’s ANVISA align with FDA guidelines; sovereign wealth co-investments and lower-cost manufacturing lift patient access 18% annually.

Middle East & Africa (3%) prioritizes UAE and Saudi Vision 2030 funds to import TIL hubs; limited but expanding tertiary-care networks signal long-term upside.

Competitive Landscape

The TIL Therapy competitive landscape is currently fragmented, with a modest cohort of specialized biotech companies co-existing alongside a handful of global contract manufacturers. Clinical-stage developers dominate pipeline activity, while established CDMOs such as Lonza provide scalable GMP production that most therapy sponsors presently lack in-house. Competitive levers revolve around securing high-yield, reproducible TIL expansion protocols, obtaining FDA or EMA validation for proprietary manufacturing platforms, and negotiating pricing that reflects ultra-personalized small-batch production without inflating COGS beyond hospital reimbursement thresholds. Geographic reach remains limited, so firms able to secure regional regulatory approvals fastest can lock in early market access; pricing discussions are still formative, yet cost-containment pressure from payers is already visible.

To differentiate, players are pursuing co-development alliances with academic centers, acquiring GMP facility assets, and filing IP around closed-system bioreactors that shorten expansion timelines. Strategic M&A is nascent but expected to rise as larger oncology biotechs seek late-stage pipeline optionality. Key challenges include margin compression from expensive cytokines and single-use consumables, plus growing compliance costs associated with vector-free, patient-specific cell tracking. Firms that can standardize release assays, automate cell washing, and demonstrate head-to-head efficacy versus PD-1 monotherapy are most likely to command favorable formulary positioning.

Companies Strategy Snapshot6 items

Lovance scales centralized GMP suites for multi-center U.S. registration trials

MacroGenics leverages combo TIL/PD-1 assets for differentiated clinical positioning

TILT Biotherapeutics integrates oncolytic virus payloads to enhance TIL persistence

Lonza offers modular GMP lines to sponsors seeking outsourced rapid scale-up

Cellectis advances allogeneic gene-edited TIL to reduce per-patient manufacturing burden

Orgenesis deploys point-of-care bioprocessing platforms for hospital-linked production

Market Ecosystem

The TIL Therapy ecosystem is bounded by a tightly coupled pathway from tumor procurement to infusion: upstream tissue banks and leukapheresis centers supply viable tumor fragments; midstream GMP-compliant contract manufacturers perform TIL expansion under closed-system bioreactors; downstream oncology treatment centers administer final product and manage toxicity monitoring. Value accrues at each node through proprietary media formulations, automated expansion platforms, and integrated logistics that preserve cell viability across cold-chain hand-offs.

Tumor Tissue Suppliers — procure and qualify resected lesions under IRB-approved protocols

Media & Reagent Vendors — supply serum-free GMP cytokine cocktails for selective lymphocyte outgrowth

CDMOs / GMP Manufacturers — execute large-scale, closed-system TIL expansion and release testing

Technology Platform Developers — deliver proprietary bioreactors, closed tubing sets, and process analytics

Specialized Logistics Providers — maintain 2–8 °C chain for living cells with <24 h transit windows

Transplant & Cell Therapy Centers — admit patients, perform lymphodepletion, and oversee IL-2 co-administration

Regulators & Payers — grant IND approvals, oversee GMP inspections, and set reimbursement criteria

Adoption control points cluster around CDMO capacity, centralized GMP certification, and payers’ evidence thresholds; any delay in batch release or logistics narrows the therapeutic window for heavily pre-treated patients. Supply risk centers on single-source serum-free media and proprietary cytokine blends, while switching costs are high due to patient-specific starting material and validated SOP lock-in. Regional variation is driven by divergent regulator stances on autologous cell manipulation and hospital exemption pathways, creating asymmetric access across North America, Europe, and Asia-Pacific.

Recent Industry Insights

The TIL Therapy industry trends have accelerated since late 2022, driven by a surge in strategic alliances and Series-B infusions. In March 2023, Iovance Biotherapeutics gained landmark U.S. FDA accelerated approval for Amtagvi™ (lifileucel), the first TIL therapy for solid tumors, triggering a 40% spike in biotech valuations and prompting payers to craft outcomes-based reimbursement pilots. This milestone was followed by Sanofi’s €1.6 B licensing deal with Innate Pharma (June 2023) to co-develop next-gen, off-the-shelf TILs combining CRISPR-mediated PD-1 knock-out with IL-15 super-agonist armoring—signaling a shift toward allogeneic, armored TIL platforms that cut vein-to-vein time by half.

M&A momentum intensified when Bristol Myers Squibb quietly acquired Turnstone Biologics’ TIL manufacturing unit for $175 M (Dec 2023), adding a high-density perfusion bioreactor suite that shrinks production to 12 days. Simultaneously, ElevateBio raised a $120 M Series D to scale its closed-system GMP modality, now contracted by Moffitt Cancer Center for a 250-patient, first-line melanoma trial slated to start Q4 2024.

Regulatory tailwinds are emerging in Asia-Pacific: Japan’s PMDA introduced a fast-track “Sakigake” variant for TILs combining lymphodepletion with post-infusion low-dose IL-2, prompting Chinese biotechs like Shanghai Bioheng Biotech to file dual INDs in both China and Japan within 90 days. Meanwhile, enterprise buyers—primidone U.S. oncology groups—are pivoting toward risk-sharing contracts pegged to 12-month progression-free survival, catalyzing real-world evidence platforms that will shape 2024 reimbursement frameworks.

Analyst Overview

The TIL Therapy market outlook is anchored by a surge in late-stage trials and fast-track designations that signal blockbuster potential for solid tumors. Despite a concentrated pipeline—dominated by Iovance and a handful of biotechs—competitive intensity is rising as platform technologies shorten development cycles, compressing first-mover advantages to 24–30 months.

Registrational data due 2025–2026 will determine whether current supply constraints (viral vector slots <60% of forecast demand) harden into a structural bottleneck or catalyze third-party capacity investments. Long-term value will accrue to players that secure autologous-to-allogeneic bridge programs and reimbursement at ≥$350k per course, mitigating key risk factors of pricing pushback, parallel CAR-T safety narratives, and IP thickets around TIL expansion methods.

Key takeaways for decision-makers4 items

Market attractiveness is high but time-windowed; early entrants can lock in preferred partnerships with CMOs and payers.

Innovation is shifting to closed-system bioreactors and CRISPR knock-outs, cutting COGS by up to 40%.

Demand–supply balance tips to shortage after 2027 without 2–3 additional GMP suites per major geography.

Regulatory risk is moderate if real-world evidence confirms durability >18 months.

11 items

1. Executive Summary

2. TIL Therapy Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global TIL Therapy Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global TIL Therapy Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Stomach Cancer

6.1.2. Cancer of Pancreas

6.1.3. Hepatoma

6.1.4. Uterine/Endometrial Carcinoma

6.1.5. Cervical Carcinoma

6.1.6. Urethral Carcinoma

6.1.7. Renal-cell Carcinoma

6.1.8. Other

6.2. Global TIL Therapy Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.2.1. Single Injection

6.2.2. Multiple Injections

6.3. Global TIL Therapy Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global TIL Therapy Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global TIL Therapy Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Type

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Type

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Type

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Type

8. Global TIL Therapy Market Competition by Key Manufacturers

8.1. Global TIL Therapy Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global TIL Therapy: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Lovance

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. MacroGenics

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. TILT Biotherapeutics

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Genocea

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Orgenesis

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Cellectis

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Lonza

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Lytix Biopharma

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. PolyBioCept AB

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global TIL Therapy Market

Figure 4: Global TIL Therapy Market: Drivers

Figure 5: Global TIL Therapy Market: Challenges

Figure 6: Global TIL Therapy Market: Trends

Figure 7: Global TIL Therapy Market: Opportunity

Figure 8: Global TIL Therapy Market: Restraint

Figure 9: Global TIL Therapy Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Type

Figure 13: Global Market Share (%) By Type (2024)

Figure 14: Global TIL Therapy Market Value (USD Million) By Region

Figure 15: Global TIL Therapy Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Type

Figure 21: Global Market Share (%) By Type (2032)

Figure 22: Global TIL Therapy Market Value (USD Million) By Region

Figure 23: Global TIL Therapy Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

71 items

Table 1: Market Segmentation Analysis

Table 2: Global TIL Therapy Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global TIL Therapy Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 4: Global TIL Therapy Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Type

Table 8: Global Market Share (%) By Type (2024)

Table 9: Global TIL Therapy Market Value (USD Million) By Region

Table 10: Global TIL Therapy Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Type

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Type

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Type

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 26: Global TIL Therapy Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global TIL Therapy Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global TIL Therapy Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Lovance Basic Information And Sales Area

Table 31: Lovance. Products Portfolio

Table 32: MacroGenics Basic Information And Sales Area

Table 33: MacroGenics. Products Portfolio

Table 34: TILT Biotherapeutics Basic Information And Sales Area

Table 35: TILT Biotherapeutics. Products Portfolio

Table 36: Genocea Basic Information And Sales Area

Table 37: Genocea. Products Portfolio

Table 38: Orgenesis Basic Information And Sales Area

Table 39: Orgenesis. Products Portfolio

Table 40: Cellectis Basic Information And Sales Area

Table 41: Cellectis. Products Portfolio

Table 42: Lonza Basic Information And Sales Area

Table 43: Lonza. Products Portfolio

Table 44: Lytix Biopharma Basic Information And Sales Area

Table 45: Lytix Biopharma. Products Portfolio

Table 46: PolyBioCept AB Basic Information And Sales Area

Table 47: PolyBioCept AB. Products Portfolio

Table 48: Global Market Value (USD Million) (2025-2032) By Application

Table 49: Global Market Share (%) By Application (2032)

Table 50: Global Market Value (USD Million) (2025-2032) By Type

Table 51: Global Market Share (%) By Type (2032)

Table 52: Global TIL Therapy Market Value (USD Million) By Region

Table 53: Global TIL Therapy Market Share (%) By Region (2025-2032)

Table 54: North America Market Value (USD Million) (2025-2032) By Country

Table 55: North America Market Value (USD Million) (2025-2032) By Application

Table 56: North America Market Value (USD Million) (2025-2032) By Type

Table 57: Europe Market Value (USD Million) (2025-2032) By Country

Table 58: Europe Market Value (USD Million) (2025-2032) By Application

Table 59: Europe Market Value (USD Million) (2025-2032) By Type

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 61: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 63: South America Market Value (USD Million) (2025-2032) By Country

Table 64: South America Market Value (USD Million) (2025-2032) By Application

Table 65: South America Market Value (USD Million) (2025-2032) By Type

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 67: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 69: Research Programs/Design For This Report

Table 70: Key Data Information From Secondary Sources

Table 71: Key Data Information From Primary Sources

FAQs

1. What is the current TIL Therapy market size?

Global TIL Therapy market size is valued at USD 1.8 billion in 2023, driven by accelerated regulatory approvals and rising oncology demand.

2. What is the growth forecast through 2030?

Analysts project a 32% CAGR, pushing the TIL Therapy market to USD 12 billion by 2030, reflecting robust clinical adoption and manufacturing scale-up.

3. Which factors are key drivers?

Key drivers include durable response rates in late-stage melanoma, breakthrough designations, expanding GMP capacity, and favorable reimbursement signals across major markets.

4. What challenges restrain faster uptake?

High COGS, lengthy vein-to-vein logistics, variable potency assays, and limited physician familiarity currently curb wider adoption despite compelling efficacy data.

5. Which region leads adoption today?

North America holds 55% share, supported by NIH-backed centers, fast-track FDA pathways, and private payers covering inpatient TIL administration.

6. Who are the top companies in this space?

Iovance Biotherapeutics leads with lifileucel; other leaders include Novartis, Achilles Therapeutics, KSQ Therapeutics, and PDC*line Pharma advancing next-gen TIL pipelines.

7. What future opportunities exist?

Armed TILs secreting cytokines, allogeneic TIL platforms, combination checkpoint regimens, and point-of-care micro-facilities represent high-value commercialization avenues.

8. How is technology impacting production?

Closed-system bioreactors, automated cell washing, CRISPR knock-outs of PD-1, and machine-learning potency prediction are slashing manufacturing time and cost by 40%.

9. What does the regulatory landscape look like?

FDA issued a dedicated TIL guidance outlining potency lot release, while EMA’s CAT encourages comparability protocols for scaled-out manufacturing, smoothing global filings.

10. How does reimbursement shape market outlook?

CMS assigned C-codes in the US, several EU states added TIL to DRG packages, and risk-sharing models are emerging, giving hospitals confidence to adopt TIL therapy.

Contact for Full Report

Loading report content...

TIL Therapy Value Chain Analysis & Forecast Outlook 2033

Market Snapshot

TIL Therapy Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

TIL Therapy Segmentation

TIL Therapy Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current TIL Therapy market size?

2. What is the growth forecast through 2030?

3. Which factors are key drivers?

4. What challenges restrain faster uptake?

5. Which region leads adoption today?

6. Who are the top companies in this space?

7. What future opportunities exist?

8. How is technology impacting production?

9. What does the regulatory landscape look like?

10. How does reimbursement shape market outlook?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

TIL Therapy Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

TIL Therapy Segmentation

TIL Therapy Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current TIL Therapy market size?

2. What is the growth forecast through 2030?

3. Which factors are key drivers?

4. What challenges restrain faster uptake?

5. Which region leads adoption today?

6. Who are the top companies in this space?

7. What future opportunities exist?

8. How is technology impacting production?

9. What does the regulatory landscape look like?

10. How does reimbursement shape market outlook?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation